The National Health Service in England has set out what it says is its “final” offer to enable patients in England to access Vertex’s cystic fibrosis drugs, including Orkambi (lumacaftor/ivacaftor). The amount offered by NHS England would represent the biggest financial commitment in its history.
While NHS England and Steve Brine, the parliamentary under-secretary of state for health and social care, have defended NICE processes...